In addition, in vitro studies in human HCC cell lines revealed that NOD2 is required to enhance sensitivity to sorafenib and lenvatinib through the activation of the adenosine 5′-monophosphate-activated protein kinase (AMPK) pathway (53). The gene discussed is NOD2; the disease is hepatocellular carcinoma.